E Fund Management (HK)’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
Other funds holding NBIX
E Fund Management (HK)'s NBIX Position: Q2 2026 in Review
E Fund Management (HK) increased its Neurocrine Biosciences (NBIX) stake by 36% in Q2 2026, buying an estimated $5.93K and bringing the position to 152 shares worth $25.6K. The position accounts for 0.01% of the portfolio, ranked #262.
E Fund Management (HK) first reported a position in NBIX in Q1 2026 and has held it in 2 quarters since. 779 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.
- E Fund Management (HK) held 152 shares of Neurocrine Biosciences worth $25.6K as of Q2 2026.
- E Fund Management (HK) bought 40 Neurocrine Biosciences shares in Q2 2026, an estimated $5.93K.
- Neurocrine Biosciences made up 0.01% of E Fund Management (HK)'s portfolio in Q2 2026, its #262 holding.
- E Fund Management (HK) first reported a position in Neurocrine Biosciences in Q1 2026 and has held it in 2 quarters since.
- 779 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.
Based on E Fund Management (HK)'s 13F filing for Q2 2026, filed 22 Jul 2026.